Drug Information

Drug General Information
Drug ID
D0XV4Z
Former ID
DNCL002821
Drug Name
TD-4208
Indication Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] Phase 3 [525280]
Company
Theravance
Target and Pathway
Target(s) Muscarinic receptor Target Info Antagonist [532360]
KEGG Pathway Calcium signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
PI3K-Akt signaling pathway
Cholinergic synapse
Regulation of actin cytoskeleton
PathWhiz Pathway Muscle/Heart Contraction
Reactome Muscarinic acetylcholine receptors
Acetylcholine regulates insulin secretion
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
Regulation of Actin Cytoskeleton
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Secretion of Hydrochloric Acid in Parietal Cells
GPCR ligand binding
GPCR downstream signaling
References
Ref 525280ClinicalTrials.gov (NCT02512510) Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD).
Ref 532360In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013 Aug;346(2):241-50.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.